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Twenty eight both children and adults were grafted with
allogeneic umbilical cord blood cells (UCB), 15 males and 13
females. Seven patients were grafted because a non-malignant
condition and 21 for a malignant disease. The median age was 8
years (range 4 months – 72 years). Ten UCB were obtained
from Mexican cord bloods banks, ﬁve cords were from compat-
ible siblings and the remaining 13 cords were obtained from
abroad. Median time to recover  0.5  109/ L granulocytes
was 24 days (range 8 – 32 days), whereas median time to recover
 20  109/ L platelets was 26 days (range 12 – 50 days) Twelve
recipients never engrafted and recovered subsequently endoge-
nous hematopoiesis. The non-engraftment rate was signiﬁcantly
higher in patients allografted for benign conditions (71%) than
in those allografted for malignant conditions (28%). The me-
dian overall post-transplant survival (SV) was 33 months and the
73-months overall SV was 39%. The cumulative incidence of
grade II–IV acute GVHD and grade III–IV GVHD for the
entire cohort of patients were 14% and 7%, respectively. Addi-
tional studies are needed to deﬁne if non-myeloablative condi-
tioning is preferable over conventional conditioning in the case
of UCB allografting.
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It has been proposed that lymphocyte recovery is associated
with transplant outcomes. We evaluated the prevalence, corre-
lates and outcome of ALC 500109/L on day 30 post SCT in
130 consecutive high-risk AML patients (pts), who received
HLA-matched unmanipulated PBSCT from a sibling donor(s-
ibling/PB, n69) or BM from a matched unrelated donor
(MUD/BM, n61) between 1996 and 2006, and who were alive
and in complete remission on day 30 post SCT. Conditioning
regimen was FM (ﬂudarabine 25-30mg/m2 for 4-5 days and
melphalan 100-180mg/m2), GVHD prophylaxis was tacrolimus
and methotrexate in 92% of pts. Results: ALC count on day 30
post SCT was signiﬁcantly lower in pts who were diagnosed
with grade II-IV acute GVHD within 30 days post SCT (n21,
median 250 109/L ) compared with grade 0-I (n109, median
650 109/L ), p0.001. Excluding pts with grade II-IV acute
GVHD, 37% of 109 patients had 500 109/L ALC on day 30.
Signiﬁcant factors associated with ALC500109/L on univar-
iate analysis included presence of circulating blasts at time of
SCT, CMV antigenemia within 30 days post SCT, and platelet
count below the median on day 30 post SCT. There was a
strong trend for lower count associated with age 57 years
(median), a higher than the median number of chemotherapy
regimens prior to SCT, and MUD/BM graft. There was no
association between ALC and gender or time to ALC
200109/L or 500109/L. These ﬁndings were consistent when
analysis was stratiﬁed by type of graft (sibling/PB and MUD/
BM) and on multivariate analysis with the exception of lower
statistical signiﬁcance for disease status at SCT. With a median
follow-up of 29 months, a landmark analysis starting at day 30
post SCT showed a signiﬁcantly higher rate of mortality and
non relapse mortality (NRM) at 3 years for pts with
ALC500109/L in recipients of a sibling/PB graft (HR OS
2.6, p 0.02 ; (HRNRM3.7, p 0.03)), but not in recipients of a
MUD/BM graft (HROS 1.2, p 0.7; HRNRM 1.3, p 0.6). There
was a trend for a higher rate of grade II-IV acute GVHD after
day 30 in the ﬁrst group (HR2.1, p 0.2) but not in the later
(HR0.6, p 0.3). There was no impact on the rate of disease
progression or chronic graft versus host disease irrespective of
the type of graft. Conclusion: In AML pts, pre- and post-
transplant factors are correlated with low ALC on day 30 post
SCT which in turn is associated with higher mortality in recip-
ients of sibling/PB transplant.
Predictors of ALC on day 30 post SCT
N
%ALC<
500109
Univariate
OR p
Multivariate
OR p
Grade II-IV aGVHD 21 76% 5.5 0.002
Grade 0-I aGVHD 109 37%
Excluding grade II-IV
aGVHD
Type of graft
sibling/PBSC 61 33%
MUD/BM 48 42% 1.5 0.3 2.1 0.1
Dose of Melphalan (mg/
m2)
100 20 25% 0.5 0.2
140/180 89 39%
Age (years)
<57 63 30%
>57 46 46% 1.9 0.09
Disease status at SCT
CR/no CR no CB* 76 29%
No CR / CB 32 53% 2.8 0.02 1.9 0.2
Lines of prior
chemotherapy lines
<median 71 31%
>median 38 47% 2 0.09
CMV antigenemia by
day 30
Positive CMV
antigenemia 20 15% 0.2 0.03 0.1 0.01
No CMV antigenemia 88 42%
Platelet count on day 30
<median 54 48% 2.7 0.015 4.2 0.01
>median 55 25%
Time to ALC 200109/L
<median 37 38% 1.1 0.9
>median 72 36%
**Time to ALC
500109/L
<median 41 32% 0.9 0.8
>median 58 31%
*CB: Circulating blasts;**evaluated in patients who recovered ALC
500109/L within 30 days
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Objective: Myeloﬁbrosis with myeloid metaplasia (MMM) is a
clonal myeloproliferative disorder of later life not generally con-
sidered for allogeneic haematopoietic cell transplantation (allo-
HCT) until recently. The natural course of the disease varies
greatly but is eventually fatal in all. We present the results of 35
consecutive transplants for MMM during the last six years in our
institution. -Material andMethods: 25 males and 10 females with
primary (n29) and secondary MMM (n6) were grafted with
unmanipulated bone marrow (n21) or peripheral stem cells
(n14) from a related (n10) or unrelated (n25) donor. Median
(md) age was 51 (33-64) years. Ten patients (pts) had low, 15
intermediate and 10 high risk disease (Dupriez score 0, 1, 2). 28 pts
had a modiﬁed Charlson comorbidity index (CCI, Diaconescu et
al, Blood 104, 2004: 1550) of 0 to 2, seven one of 3 to 6. Karyo-
typing was successful in 29 pts and abnormal in 12. All but four pts
received intermediate intensity conditioning (TBI(8Gy)/Flud/Cy n
 21 or Bu(10)/Flud n  10). In all unrelated and two related
transplants rabbit ATG was added before grafting. - Results: All
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